Fig. 2
The effect of combining E6-siRNA and Oxaliplatin on the viability of CaSki cancerous cells and E6 expression. A, B. In the Oxaliplatin and siRNA combination, the drug’s IC50 was reduced compared to only chemotherapy with Oxaliplatin. C. The expression rate of E6 oncogene in combination therapy decreased significantly compared to other groups (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)